Key Highlights

  • Total Revenue was USD 2.22 million, against an estimate of USD 2.71 million.
  • Net loss per share was USD 2.44, against an estimate of a USD 2.60 loss.
  • Clinic revenue rose to USD 2.21 million from USD 1.72 million.
  • Cash was USD 3.70 million at September 30, 2026.

INVO Fertility (NASDAQ:IVF) saw its clinics grow in the third quarter of 2026, yet total revenue of USD 2.22 million, up from USD 1.76 million, fell short of the USD 2.71 million estimate. Clinic revenue was USD 2.21 million, compared with USD 1.72 million, while product revenue declined to USD 15,069 from USD 34,871. Basic and diluted net loss per common share was USD 2.44, compared with USD 157.43, against an estimate of a USD 2.60 loss.

Costs and the Operating Loss

Cost of services was USD 1.44 million, compared with USD 1.12 million. Selling, general and administrative expenses were USD 2.07 million, compared with USD 2.13 million, and Depreciation and amortization was USD 177,564, compared with USD 136,741. Total operating expenses were USD 3.70 million, compared with USD 3.39 million, and the loss from operations was USD 1.48 million, compared with USD 1.64 million.

The change in Fair Value of Derivatives was a loss of USD 562,997, interest income was USD 74,735 and interest expense was USD 154,768, compared with USD 322,765. Total other expense was USD 643,030, compared with USD 1.76 million.

Net Loss and the Nine Months

The net loss from continuing operations was USD 2.15 million, compared with USD 3.40 million, after a provision for income taxes of USD 29,530. For the nine months, total revenue was USD 6.41 million, compared with USD 5.26 million, and net loss per common share was USD 11.20, compared with USD 722.84 for continuing operations in the prior-year period. Per share amounts reflect the number of shares outstanding in each period as presented in the filing.

For the nine months, the filing shows a USD 172,621 loss on Debt extinguishment, a USD 2.45 million gain on remeasurement and a USD 4.35 million loss from the change in fair value of derivatives. Selling, general and administrative expenses for the nine months were USD 6.15 million, compared with USD 5.88 million, and the loss from operations was USD 4.36 million, compared with USD 5.83 million.

Balance Sheet and Going Concern Doubt

Cash was USD 3.70 million at September 30, 2026, compared with USD 2.08 million at December 31, 2025. Total Assets were USD 25.50 million, compared with USD 20.22 million, and Goodwill was USD 9.24 million. The Balance Sheet includes an Investment in NAYA Therapeutics of USD 2.47 million and a note receivable from NAYA Therapeutics of USD 5.24 million.

Total liabilities were USD 7.49 million, compared with USD 13.00 million, and total current liabilities were USD 4.46 million, compared with USD 10.33 million. The filing states substantial doubt over going concern status for at least a year after the financial statements were issued, and says more Capital would have to be raised.